Oncoclínicas Q2 2026 slides: EBITDA turns positive despite revenue drop

Brazilian oncology provider Oncoclínicas reported improved financial performance in its second quarter of 2026, with positive adjusted EBITDA and operating cash flow despite a decline in revenue. The company's stock rose 29.87% to $1.00 following the presentation. The quarter was marked by a medication supply crisis, medication shortages, and one-time accounting charges.

Despite a 25.9% drop in gross revenue to R$1,227.6 million, adjusted EBITDA turned positive at R$34.3 million, a 3.3% margin. Normalizing for the provision for loan losses, the adjusted EBITDA margin reached 9.5%. Operating cash flow turned positive at R$158.4 million, reflecting improved working capital management. Capital expenditures remained low at R$13.3 million, with a net debt of R$3.4 billion.

The company's net loss for the quarter was R$275.3 million, but the trailing twelve-month adjusted net loss stood at R$1,350.8 million.